# SI-BONE, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/SI-BONE, Inc.). ## Overview SI-BONE, Inc. develops and commercializes implant systems and surgical instruments for sacropelvic conditions, with a core focus on minimally invasive treatment of sacroiliac joint dysfunction and degeneration. The company is based in the United States and sells through direct and partner sales channels in the U.S. and selected international markets, including Europe. ## Products & services • iFuse implant systems for sacroiliac joint fusion • iFuse 3D titanium implants and instruments • iFuse TORQ and iFuse TORQ TNT systems • iFuse Bedrock Granite for sacropelvic fixation • iFuse INTRA for pelvic trauma applications • Implantable bone products and procedure instruments - **Sacroiliac joint fusion systems** (55%) — Minimally invasive implants and instruments used to treat sacroiliac joint dysfunction and degeneration. - **Thoracolumbar fixation and fusion** (20%) — Implant systems designed for adult spinal deformity and thoracolumbar stabilization procedures. - **Pelvic trauma fixation** (15%) — Implants and tools used in pelvic fracture fixation and trauma-related procedures. - **Implantable bone products and accessories** (10%) — Adjunct bone products, instruments, and procedure support items used with the implant portfolio. - iFuse implant systems for sacroiliac joint fusion - iFuse 3D titanium implants and instruments - iFuse TORQ and iFuse TORQ TNT systems - iFuse Bedrock Granite for sacropelvic fixation - iFuse INTRA for pelvic trauma applications - Implantable bone products and procedure instruments ## Customers SI-BONE sells primarily to surgeons and hospitals that perform minimally invasive sacropelvic and spine procedures. Its products are used by orthopedic surgeons, spine surgeons, and other physicians treating sacroiliac joint disease, adult spinal deformity, and pelvic trauma. Purchasing decisions are influenced by clinical evidence, ease of use, training support, reimbursement coverage, and procedure outcomes. - **Orthopedic and spine surgeons** (primary) — Buy implant systems and instruments for sacroiliac fusion, spinal fixation, and pelvic trauma procedures because they need clinically supported, anatomy-specific solutions. - **Hospitals and surgical facilities** (primary) — Purchase or consignment-use trays, implants, and procedure support items to enable cases and maintain inventory availability. - **Healthcare systems and payors** (secondary) — Influence adoption through reimbursement coverage and payment policies that affect procedure economics. - **International distributors and resellers** (secondary) — Buy or distribute products in non-U.S. markets where SI-BONE uses a mixed direct and partner model. - Orthopedic surgeons performing sacroiliac fusion and pelvic fixation - Spine surgeons treating adult spinal deformity and thoracolumbar cases - Hospitals and ambulatory sites that stock implants and trays - Physicians who value clinical evidence and procedure simplicity - Health systems seeking reimbursable minimally invasive solutions ## Geography The United States is the company’s core market and accounted for 95% of revenue in 2025, with international markets contributing the remaining 5%. International activity is concentrated in Europe and other selected markets where SI-BONE uses direct sales, agents, and resellers. Geography matters because the business depends on U.S. reimbursement, while international growth requires regulatory clearances and local commercial coverage. - **United States** (95%) — 2025 annual revenue by geography - **International** (5%) — 2025 annual revenue by geography - United States generated 95% of 2025 revenue - International revenue was 5% of 2025 revenue - Direct sales force is concentrated in the U.S. - Europe is the main disclosed international operating region - Revenue is billed by customer address, not procedure site ## Strategy SI-BONE’s strategy centers on expanding procedure volume by broadening its product portfolio and increasing the number of active physicians using its systems. The company is also focused on improving sales-force productivity, deploying instrument trays more efficiently, and tightening supply-chain and manufacturing execution to support growth. These priorities reinforce its position in anatomy-specific, minimally invasive sacropelvic surgery. - **Grow procedure volume through portfolio expansion** (medium-term) — More indications and product lines increase the number of cases a surgeon can treat with SI-BONE systems. - **Improve commercial productivity** (short-term) — Higher sales-force efficiency supports broader physician coverage without proportional overhead growth. - **Strengthen supply and manufacturing execution** (short-term) — Reliable implant availability and lower rework are important in procedure-driven medical device sales. - Expand the installed base of physicians using iFuse systems - Increase territory sales productivity and case coverage capacity - Deploy instrument trays more efficiently across active sites - Improve supply-chain resilience and reduce implant lead times - Use design-for-manufacturing to lower cost and waste over time - Integrate demand planning with manufacturing execution ## Risks SI-BONE faces competition from other implant and spine companies, and adoption depends on clinical evidence, reimbursement, and surgeon preference. The business is also exposed to supply-chain disruptions, sterilization dependencies, regulatory scrutiny around physician relationships, and cybersecurity risks tied to sensitive data and connected systems. - **Intense competition in sacropelvic and spine implants** [high] — Surgeons can choose alternative products based on evidence, ease of use, and reimbursement. - **Supply-chain and sterilization disruptions** [high] — The company relies on third-party suppliers for materials, components, and sterilization services. - **Regulatory scrutiny of physician financial relationships** [high] — Consulting, royalty, and co-marketing arrangements may be challenged under anti-kickback laws. - **Cybersecurity and data privacy incidents** [medium] — A breach could expose confidential information, disrupt systems, and create legal liability. - **Sales-force retention and productivity risk** [medium] — The model depends on trained reps and agents who support surgeons and case coverage. - Competition can pressure adoption, pricing, and reimbursement access - Supply disruptions can delay implants and sterilized product availability - Physician relationship arrangements can trigger anti-kickback scrutiny - Cybersecurity incidents could disrupt operations and damage trust - Sales-force turnover can slow training and reduce case coverage ## Accounting Revenue recognition is a key accounting area because sales are tied to product shipments, consignment arrangements, and procedure-driven demand. Investors should also watch seasonality, since the company has historically seen lower summer sales and stronger fourth-quarter activity, which affects quarter-to-quarter comparability. Estimates around inventory, instrument trays, and other operating assets can also influence reported margins and asset utilization. - **Revenue recognition** — Quarterly revenue timing and comparability - **Seasonality** — Quarterly trend interpretation - **Inventory and instrument tray capitalization** — Working capital and gross margin - **Estimates and judgments** — Reported earnings and balance-sheet values - Revenue timing can vary with shipments, consignment, and case usage - Seasonality can make quarterly revenue and margins uneven - Inventory and tray investments affect working capital and utilization - Estimates and assumptions affect reported assets and liabilities - Potential impairment or reserve judgments can affect earnings --- *Last updated: 2026-04-29T04:55:16.021240+00:00*